An insulin-conjugated dual SLC2A1/SLC2A4 inhibitor for diabetes

DISEASE CATEGORY: Endocrine/metabolic

INDICATION: Diabetes

A team led by Zenomics Inc. scientific co-founder Zhen Gu identified an insulin-conjugated

Read the full 164 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE